These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1625897)

  • 21. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
    Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
    Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhancement of erectile responses to vasoactive drugs by a variable amplitude oscillation device.
    Chun SS; Fenemore J; Heaton JP; Johnston B; Morales A
    Int J Impot Res; 1996 Dec; 8(4):221-5. PubMed ID: 8981171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O; Hanani J; Shalhav A; Vardi Y; Goldwasser B
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate.
    Israilov S; Niv E; Livne PM; Shmueli J; Engelstein D; Segenreich E; Baniel J
    Int J Impot Res; 2002 Feb; 14(1):38-43. PubMed ID: 11896476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intracavernous pharmacotherapy for management of erectile dysfunction in spinal cord injury.
    Lloyd LK; Richards JS
    Paraplegia; 1989 Dec; 27(6):457-64. PubMed ID: 2608299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The combined use of sex therapy and intrapenile injections in the treatment of impotence.
    Kaplan HS
    J Sex Marital Ther; 1990; 16(4):195-207. PubMed ID: 2079703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intracavernosal injection therapy for impotence: preliminary results.
    Gilling PJ; Wright WL; Gray JM
    N Z Med J; 1988 Jun; 101(848):423-4. PubMed ID: 3393333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Self intra-cavernous injections as a successful treatment in pure neurogenic impotence.
    Greco E; Balbi PP; Virag R
    Riv Neurol; 1991; 61(1):35-8. PubMed ID: 1857921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intracavernous auto-injection therapy with papaverine phentolamine via an auto-injection pen for patients with an erectile dysfunction: similar results achieved in family practice and urology].
    de Boer BJ; Lycklama a Nijeholt AA; Kleinjans HA
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):783-7. PubMed ID: 11346917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction.
    Chao R; Clowers DE
    Arch Phys Med Rehabil; 1994 Mar; 75(3):276-8. PubMed ID: 8129578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [3 years' experience with intracavernous auto-injection therapy].
    Weiske WH
    Urologe A; 1989 Sep; 28(5):253-6. PubMed ID: 2815435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
    von Heyden B; Donatucci CF; Kaula N; Lue TF
    J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Percutaneous use of vasoactive drugs in the diagnosis and treatment of erectile impotence].
    Pastorini S; Marino G; Cocimano V; Marten Perolino R
    Minerva Urol Nefrol; 1992; 44(3):191-3. PubMed ID: 1492270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group.
    Linet OI; Ogrinc FG
    N Engl J Med; 1996 Apr; 334(14):873-7. PubMed ID: 8596569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Short term use of intracavernous vasoactive drugs in the treatment of persistent psychogenic erectile dysfunction.
    Ghanem H; Sherif T; Adbel-Gawad T; Asaad T
    Int J Impot Res; 1998 Dec; 10(4):211-4. PubMed ID: 9884916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intracavernous injections of vasoactive substances for the treatment of impotence.
    Zorgniotti AW
    Nihon Hinyokika Gakkai Zasshi; 1985 Nov; 76(11):1620. PubMed ID: 3835353
    [No Abstract]   [Full Text] [Related]  

  • 38. Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction.
    Kaplan SA; Reis RB; Kohn IJ; Shabsigh R; Te AE
    Urology; 1998 Nov; 52(5):739-43. PubMed ID: 9801091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
    Lee LM; Stevenson RW; Szasz G
    J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracavernous injection of papaverine, phentolamine and phenoxybenzamine.
    Pettirossi O; Serenelli G
    Acta Urol Belg; 1988; 56(2):211-9. PubMed ID: 3400527
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.